Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
131 hedge funds and large institutions have $987M invested in Esperion Therapeutics in 2017 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 51 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
52% more capital invested
Capital invested by funds: $647M → $987M (+$340M)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
13.51% more ownership
Funds ownership: 81.22% → 94.73% (+14%)
10% more funds holding
Funds holding: 119 → 131 (+12)
24% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 51
71% less call options, than puts
Call options by funds: $29.9M | Put options by funds: $103M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$40.2M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$21.5M |
| 3 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$20.8M |
| 4 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$11.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
PDT Partners
New York
|
-$11.1M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$10.1M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$6.62M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$5.44M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.09M |
ESPR Hedge Fund Activity: Q2 2017 in Review
131 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2017, worth a combined $987M — up 52% from $647M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ESPR positions and 13 closed out — a net gain of 13 holders — while 39 added to existing stakes and 51 trimmed.
The largest buyer was State Street, adding an estimated $40.2M. The largest seller was PDT Partners, exiting entirely with an estimated $11.1M sold.
- 131 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2017, up from 119 in Q1 2017.
- Funds reported $987M of Esperion Therapeutics stock for Q2 2017, up 52% quarter-over-quarter.
- 26 funds opened new Esperion Therapeutics positions in Q2 2017 and 13 closed out, a net change of +13 holders.
- The largest Esperion Therapeutics buyer in Q2 2017 was State Street, an estimated $40.2M added.
- The largest Esperion Therapeutics seller in Q2 2017 was PDT Partners, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2017.